LIPO-5

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), French National Agency for Research on AIDS and Viral Hepatitis, ANRS, Emerging Infectious Diseases

Conditions

HIV InfectionHIV Infections

Phase 1

A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines

CompletedNCT00076063

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2004-03-31End: 2007-03-31Updated: 2021-10-14

Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers

CompletedNCT02038842

ANRS, Emerging Infectious DiseasesHIV Infection

Start: 2014-03-01End: 2016-03-01Updated: 2026-04-14

Phase 2

AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers

CompletedNCT00121758

French National Agency for Research on AIDS and Viral HepatitisHIV Infections

Start: 2004-09-30End: 2007-12-31Target: 156Updated: 2008-06-06

Related Papers

Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants

Clinical and Vaccine Immunology2014-09-2411 citations

Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.

2007-08-2227 citations